Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in South Korea / NCT02558699
Recruiting Not applicable

Clinical Usefulness of Virtual Ablation Guided Catheter Ablation of Atrial Fibrillation: Virtual Rotor Mapping and Catheter Ablation

NCT02558699 · tracked via the Priya Life Science South Korea tracker
Sponsor
Yonsei University
Phase
Not applicable
Started
2018-08-24
Last updated
2023-01-03

Condition(s) studied

Paroxysmal Atrial Fibrillation

Investigational drug(s) / intervention(s)

physician's personal experienceVirtual rotor mapping

physician's personal experience: physician's personal experience

Virtual rotor mapping: Virtual rotor mapping

Study summary

Radiofrequency catheter ablation is effective in the treatment of patients with paroxysmal atrial fibrillation. In order to reduce the recurrence rate after catheter ablation, the investigators propose to apply 'virtual' ablation on patient-specific atria by simulating 3D atrial computer model. The investigators will conduct virtual rotor mapping in the patient specific atrial model. Then, the investigators will compare the clinical outcome of conventional circumferential pulmonary vein isolation and additional rotor ablation guided by virtual rotor mapping.

Eligibility

Sex
ALL
Min age
19 Years
Max age
80 Years
Healthy volunteers
No
Inclusion Criteria: * AF patient age 19\~80 * Diagnosis of AF patients who performed catheter ablation of atrial fibrillation due to uncontrolled pulse rate by anti-arrhythmic drug therapy. Exclusion Criteria: * AF patients who have severe heart deformations or vascular disease. * The patient who have renal disease of eGFR\<30mL/min * The patients who had been performed catheter ablation of atrial ablation and MAZE. * The patients who missed out to recording of 3D CT, echo and electrocardiography. * the patient have experienced major hemorrhagic complication * The patient have experienced ischemic cerebral infarction more 2 times * The patient who have risk of ischemic cerebral infarction (CHA2DS2-VASc Score \>5)

Primary outcome measure(s)

  • Recurrence rate of atrial fibrillation of 18 months after procedure within 18 months — 18 months
  • Rate of mortality, incidence of cerebral infarction and hospitalization after procedure — 24 months

Trial sites (1)

FacilityCityRegionStatus
Severance Cardiovascular Hospital, Yonsei University Health System Seoul South Korea Recruiting

More Yonsei University trials in South Korea

Concurrent Neoadjuvant Chemoradiotherapy Plus Durvalumab (MEDI4736) in Resectable Stage III NSCLC Recruiting
Aspirin vs Clopidogrel After TAVR Recruiting
Clinical Effectiveness of a Motivational Interviewing-Based Conversational Mobile Application for High-Risk Drinkers Recruiting
Study of Induction PD-1 Blockade (Nivolumab) in Patients With Surgically Complete Resectable Mismatch Repair Deficient Endometrial Cancer (NIVEC) Recruiting
Home-based Rehabilitation Monitoring System With Wearable Devices and Self-Report Application Active, not recruiting

Other trials for the same condition

Pulmonary Vein Isolation Strategy of Very High Power Short Duration in Patients With Paroxysmal Atrial Fibrillation Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT02558699 on ClinicalTrials.gov ↗ ← All trials in South Korea